Awakn Life Sciences Inc.

Recent News

  • Awakn Chief Medical Officer, Dr. Ben Sessa, Announces Results of the World's First 'MDMA in Alcohol Use Disorder' Clinical Trial

    London, United Kingdom--(Newsfile Corp. - February 19, 2021) - Awakn Life Sciences Inc. announces today the publication of results from its CMO Dr. Ben Sessa's Bristol Imperial MDMA in Alcoholism (BIMA) trial, an open-label safety, tolerability and proof-of-concept study investigating the potential role for MDMA-Assisted Psychotherapy in treating patients with alcohol use disorder (AUD).Results published today in the Journal of Psychopharmacology, show that MDMA-Assisted Psychotherapy (3,4-methylenedioxymethamphetamine) was well tolerated by all participants. No unexpected adverse events were observed, and psychosocial...

    2021-02-19 8:59 AM ET
  • Awakn Appoints James Collins, Ex-Accenture Strategy MD, as Chief Operating Officer

    London, United Kingdom--(Newsfile Corp. - January 25, 2021) - Awakn Life Sciences Inc., a biotechnology company focused on research, development, and delivery of psychedelic medicines for the treatment of mental health conditions, today announced the appointment of James Collins as Chief Operating Officer, effective January 2021.Collins joins from Accenture Strategy where he was a Managing Director (London) for several years, responsible for client relationship development, sales, delivery, and European & Global practise management. He is an industry thought leader with...

    2021-01-25 7:00 AM ET
  • Awakn Strengthens Scientific and Medical Leadership with Appointment of Chief Science Officer and Head of Ketamine Alcohol Use Disorder Practice

    Toronto, Ontario--(Newsfile Corp. - January 19, 2021) -  Awakn Life Sciences Inc., a biotechnology company focused on research, development and delivery of psychedelic medicines for the treatment of mental health conditions, today announced the appointment of Dr. Shaun McNulty, formerly at GlaxoSmithKline (GSK), as Chief Science Officer and Prof. Celia Morgan, from Exeter University, as Head of Ketamine-Assisted Psychotherapy for the company's Alcohol Use Disorder (AUD) Practice; both effective January 2021.Dr. McNulty joins as an experienced biotechnology executive with over...

    2021-01-19 7:00 AM ET
  • Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use Disorder

    Toronto, Ontario--(Newsfile Corp. - January 15, 2021) - Awakn Life Sciences announced today the selection of contract research organization ('CRO'), PRA Health Sciences (NASDAQ: PRAH), to conduct a Phase IIb trial studying the effectiveness of MDMA-Assisted Psychotherapy as a treatment for patients with Non-Physically Dependent ('Harmful Use') Alcohol Use Disorder ("AUD").Awakn's Phase IIb study will take place in the United Kingdom and will be a double-blind, placebo-controlled clinical trial designed to investigate the safety and efficacy of MDMA as a...

    2021-01-15 7:00 AM ET
  • Celia Morgan, Professor of Psychopharmacology at University of Exeter and Leading Ketamine Investigator, Joins AWAKN Life Sciences

    Toronto, Ontario--(Newsfile Corp. - October 2, 2020) - AWAKN Life Sciences Inc. ("AWAKN") is pleased to announce the appointment of Professor Celia Morgan to its Scientific Advisory Board (SAB).Celia Morgan is a Professor of Psychopharmacology at the University of Exeter in the United Kingdom. She is one Europe's leading Ketamine researchers & investigators and the academic lead for the Exeter Translational Addiction Partnership. Prof. Morgan's research focuses on examining both the benefits and side effects of recreational drugs on...

    2020-10-02 8:00 AM ET
  • Dr. Michael Mithoefer & Ann Mithoefer from MAPS Join AWAKN's Scientific Board

    Toronto, Ontario--(Newsfile Corp. - September 24, 2020) - AWAKN Life Sciences Inc. ("AWAKN") is pleased to announce the appointment of Dr. Michael Mithoefer and Ann Mithoefer to its Scientific Advisory Board (SAB). Dr. Mithoefer, Senior Medical Director for Medical Affairs, Training and Supervision at MAPS Public Benefit Corporation (MPBC), has, has worked with MAPS since 2000, while Ann Mithoefer, a registered Nurse and Lead MDMA-Assisted Psychotherapy PTSD Investigator at MAPS, has worked with MAPS since 2004. Together Dr. Michael...

    2020-09-24 11:06 AM ET
  • AWAKN Life Sciences Launches Clinical Research Division with Prof. David Nutt & Dr. Ben Sessa Identifying Suitable Studies Across Europe & North America

    Toronto, Ontario--(Newsfile Corp. - September 8, 2020) - AWAKN Life Sciences Inc ("AWAKN"), the European psychedelic assisted psychotherapy company, today announces the launch of its Commercial Clinical Research Division.AWAKN's purpose is broadening access to psychedelic assisted psychotherapy and integrating these services into mainstream mental healthcare in Europe across three business divisions of Clinical Research, Therapeutic Clinics, and Practitioner Training. AWAKN's Commercial Clinical Research Division focuses on sponsoring, designing and delivering existing compound, new indication psychedelic assisted psychotherapy clinical trials,...

    2020-09-08 7:00 AM ET
  • Dr. Matthew Johnson Joins AWAKN Life Sciences

    Toronto, Ontario--(Newsfile Corp. - September 2, 2020) - AWAKN Life Sciences Inc. ("AWAKN") is pleased to announce the appointment of Dr. Mathew Johnson, Ph.D, to its Scientific Advisory Board (SAB).Dr. Johnson is one of the world's most published scientists on the human effects of psychedelics. He has conducted seminal research in the behavioral economics of drug use, addiction, and risk behavior through his role of Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University.Dr. Johnson published psychedelic safety...

    2020-09-02 2:08 PM ET